American Heart Journal
Volume 151, Issue 5 , Pages 949-955 , May 2006

Management of elderly patients with congestive heart failure—Design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

  • Hans Peter Brunner–La Rocca, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
    • ,
  • Peter Theo Buser, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
    • ,
  • Ruth Schindler, RN

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
    • ,
  • Alain Bernheim, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
    • ,
  • Peter Rickenbacher, MD

      Affiliations

    • Division of Cardiology, Kantonsspital Bruderholz, Bruderholz, Switzerland
    • ,
  • Matthias Pfisterer, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
    • Corresponding Author InformationReprint requests: Matthias Pfisterer, MD, FESC, FACC, FAHA, Head Division of Cardiology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland.
    • ,
  • for the TIME-CHF-Investigators

Received 7 July 2005 ,Accepted 20 October 2005.

References 

  1. Ni H. Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey. Am Heart J. 2003;146:121–128
  2. Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202
  3. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126–1131
  4. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23:1867–1876
  5. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev. 2002;7:9–16
  6. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4:361–371
  7. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet. 2003;362:147–158
  8. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682–1688
  9. Abdelhafiz AH. Heart failure in older people: causes, diagnosis and treatment. Age Ageing. 2002;31:29–36
  10. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954
  11. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283
  12. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130
  13. Mathew ST, Gottdiener JS, Kitzman D, et al. Congestive heart failure in the elderly: the Cardiovascular Health Study. Am J Geriatr Cardiol. 2004;13:61–68
  14. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J. 2004;25:1214–1220
  15. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–1140
  16. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106–1107
  17. Muller-Nordhorn J, Roll S, Willich SN. Comparison of the short form (SF)–12 health status instrument with the SF-36 in patients with coronary heart disease. Heart. 2004;90:523–527
  18. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651–654
  19. Vaccarino V, Kasl SV, Abramson J, et al. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 2001;38:199–205
  20. Zuccala G, Onder G, Pedone C, et al. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology. 2001;57:1986–1992
  21. Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016–1024
  22. Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346:1061–1066
  23. Krumholz HM, Phillips RS, Hamel MB, et al. Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation. 1998;98:648–655
  24. Marie PY, Mertes PM, Hassan-Sebbag N, et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol. 2004;43:353–359
  25. Ohta Y, Watanabe K, Nakazawa M, et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol. 2000;36(Suppl 2):S19–S23
  26. Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol. 2004;94:448–453
  27. Fung JW, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 2003;92:406–410
  28. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282–2289
  29. Pernenkil R, Vinson JM, Shah AS, et al. Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol. 1997;79:216–219
  30. Dupont WD, Plummer WD. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116–128

 This study is sponsored by the Horten Foundation, Lugano, Switzerland, as well as by unrestricted grants from AstraZeneca Pharma, Menarini Pharma, Novartis Pharma, Pfizer Pharma, Servier (all Switzerland with equal contributions), Roche Diagnostics, Roche Pharma, and Merck Pharma, Switzerland.

PII: S0002-8703(05)01006-9

doi: 10.1016/j.ahj.2005.10.022

American Heart Journal
Volume 151, Issue 5 , Pages 949-955 , May 2006

Article Tools

* Image Usage & Resolution